(firstQuint)Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain.

 This is an enriched enrollment, randomized withdrawal study with an open label, dose-titration period followed by a randomized, double-blind, placebo-controlled treatment period of 12 weeks.

 During the double-blind treatment period, this study will evaluate the effectiveness of buprenorphine HCl buccal film versus placebo buccal film in treating CLBP in subjects.

 Buprenorphine HCl buccal film is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa.

 Buprenorphine is a synthetic opioid that is classified as a partial mu -receptor agonist and a Schedule III controlled substance in the United States.

.

 Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain@highlight

The purpose of this study is to determine whether buprenorphine hydrochloride (HCl) buccal film is effective and safe in the treatment of chronic low back pain (CLBP).

